Menopausal Women Increase Cardiovascular Risk By 38% With Hormone Treatment Tibolone
Feb 28, 2025
Domestic researchers have published the results of a study that analyzed the relationship between menopause hormone therapy (MHT) and cardiovascular disease (CVD) risk.
This study was conducted based on large-scale health insurance data of Korean women, suggesting that the use of certain hormone treatments may increase the risk of cardiovascular disease.
A research team led by Professor Yuk Jin-sung of obstetrics and gynecology at Sanggye Paik Hospital at Inje University and Professor Kim Byung-kyu of cardiology compared and analyzed the risk of menopause hormone treatment and cardiovascular disease in 268,596 women over the age of 40 who experienced menopause from 2011 to 2014.
Studies have shown a 22% increased risk of developing cardiovascular disease in women who received postmenopausal hormone therapy.
In particular, when tibolone (Tibolone) was used, the risk of cardiovascular disease increased by 38%, whereas estrogen monotherapy or estrogen/progestogen combination therapy did not show a significant overall increase in risk. Moreover, the risk of cardiovascular disease tended to decrease when dydrogesterone was included during the combination therapy.
Professor Yuk Jin-Sung, the first author, explained that "Cardiovascular risk should be considered when receiving pulmonary hormone therapy, but not all treatments have the same effect" and that "particularly, the use of tibolone should be prudent, but some progestogen-containing combinations may have cardiovascular protective effects.' It is also necessary to provide customized treatment strategies to menopausal women based on the results of this study," he added.
Corresponding author Professor Kim Byung-kyu said, "This study has important implications in that it provides a practical clinical basis based on large-scale data of Korean women. Menopausal women considering hormone therapy should consider long-term cardiovascular health beyond just alleviating menopausal symptoms."," he stressed. In addition, "In the sense that certain hormone therapy can reduce the risk of cardiovascular disease, further studies based on this are needed in the future."
The study was published in the latest edition of the European Journal of Endocrinology (Citation Index 5.8), an international academic journal, and is expected to provide an important basis for long-term safety evaluation of menopause hormone treatment and establishing individual customized treatment strategies.
This study was conducted based on large-scale health insurance data of Korean women, suggesting that the use of certain hormone treatments may increase the risk of cardiovascular disease.
A research team led by Professor Yuk Jin-sung of obstetrics and gynecology at Sanggye Paik Hospital at Inje University and Professor Kim Byung-kyu of cardiology compared and analyzed the risk of menopause hormone treatment and cardiovascular disease in 268,596 women over the age of 40 who experienced menopause from 2011 to 2014.
Studies have shown a 22% increased risk of developing cardiovascular disease in women who received postmenopausal hormone therapy.
In particular, when tibolone (Tibolone) was used, the risk of cardiovascular disease increased by 38%, whereas estrogen monotherapy or estrogen/progestogen combination therapy did not show a significant overall increase in risk. Moreover, the risk of cardiovascular disease tended to decrease when dydrogesterone was included during the combination therapy.
Professor Yuk Jin-Sung, the first author, explained that "Cardiovascular risk should be considered when receiving pulmonary hormone therapy, but not all treatments have the same effect" and that "particularly, the use of tibolone should be prudent, but some progestogen-containing combinations may have cardiovascular protective effects.' It is also necessary to provide customized treatment strategies to menopausal women based on the results of this study," he added.
Corresponding author Professor Kim Byung-kyu said, "This study has important implications in that it provides a practical clinical basis based on large-scale data of Korean women. Menopausal women considering hormone therapy should consider long-term cardiovascular health beyond just alleviating menopausal symptoms."," he stressed. In addition, "In the sense that certain hormone therapy can reduce the risk of cardiovascular disease, further studies based on this are needed in the future."
The study was published in the latest edition of the European Journal of Endocrinology (Citation Index 5.8), an international academic journal, and is expected to provide an important basis for long-term safety evaluation of menopause hormone treatment and establishing individual customized treatment strategies.
|
This article was translated by Naver AI translator.
